Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
RSS

ASC-40 reduces liver fat in phase II China cohort in NASH

March 9, 2021

Anti-inflammatory peptide amphiphiles reduce inflammation in Crohn's disease-like ileitis model

March 8, 2021

Landos reports positive phase I data for NX-13

March 5, 2021

Arena reports phase IIb data on olorinab for abdominal pain associated with IBS

March 3, 2021

Dosing begins in first-in-human study of oral AMT-126

March 3, 2021

New Janus kinase inhibitors synthesized at Vimalan Biosciences

March 2, 2021

Promising interim data presented from SAD portion of MORF-057 phase I program

March 2, 2021

FDA approves Humira for pediatric patients with ulcerative colitis

Feb. 25, 2021

Shenzhen Chipscreen Biosciences identifies new THR beta agonists

Feb. 25, 2021

Heparegenix patents MAP2K4 inhibitors

Feb. 25, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...